Immune checkpoint inhibitor-induced rheumatoid arthritis: insights into an increasingly common aetiology of polyarthritis

被引：3

作者：

Kwok, Timothy Shun Him ^{[1
]}

Bell, Mary Jane ^{[2
,3
]}

机构：

[1] Univ Toronto, Dept Med, Toronto, ON, Canada

[2] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada

[3] Univ Toronto, Dept Med, Div Rheumatol, Toronto, ON, Canada

来源：

BMJ CASE REPORTS | 2019年 / 12卷 / 02期

关键词：

cancer intervention; medical management; unwanted effects; adverse reactions; rheumatology; drugs: musculoskeletal and joint diseases;

D O I：

10.1136/bcr-2018-227995

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Nivolumab is an immune checkpoint inhibitor that is used in the treatment of a variety of cancers in the adjuvant or metastatic setting. Adverse effects include non-specific activation of T cells, leading to immune-related adverse events in downstream organs. We present a case of a 36-year-old man with unresectable oropharyngeal squamous cell carcinoma who developed nivolumab-induced rheumatoid arthritis. As immune checkpoint inhibitor use is becoming widespread in the medical oncology domain, the purpose of this case report is to increase awareness of an increasingly common cause of rheumatic disease and to alert clinicians to consider immunotherapy in their differential diagnosis of polyarthritis. This case also highlights the importance of working in an interdisciplinary manner to enhance cancer care for the patient as well as to increase awareness of the potential adverse effects of immunotherapy in patients with cancer.

引用

页数：3

共 11 条

[1] Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment [J].